Onesource Specialty Pharma
NSE: ONESOURCE · ISIN INE013P01021 · Healthcare
₹1,620.10−12.50 (−0.77%)
Monday 9 November, 12:18 IST. Delayed. Source: Yahoo Finance.
Price chart
₹1,620.10 −12.50 (−0.77%) today
The day
- Previous close
- ₹1,632.60
- Open
- ₹1,633.00
- Day high
- ₹1,649.80
- Day low
- ₹1,609.50
Listed on NSE since 24 January 2025.
Key numbers
- Market value
- ₹18,346 Cr
- EPS (trailing)
- ₹-0.15
- Price to book
- 3.10
- Dividend yield
- 0.00%
- Return on equity
- -0.0%
- Debt to equity
- 0.30
- Profit margin
- -0.1%
- Volume today
- 1.15 L
- Average volume
- 4.67 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹38.71 Cr | ₹-799.83 Cr |
| FY24 | ₹171.92 Cr | ₹-391.17 Cr |
| FY25 | ₹1,444.85 Cr | ₹-17.97 Cr |
| FY26 | ₹1,421.59 Cr | ₹-73.80 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹965 Cr | ₹82 Cr | +686.7% |
| Q1 FY27Apr–Jun 2026 | ₹449 Cr | ₹0 | – |
| Q4 FY26Jan–Mar 2026Audited | ₹428 Cr | ₹5 Cr | −95.3% |
| Q3 FY26Oct–Dec 2025 | ₹290 Cr | ₹-89 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹376 Cr | ₹10 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹327 Cr | ₹-18.60 L | – |
Source: Onesource Specialty Pharma’s results filed with NSE, consolidated (the whole group). Net profit is the share of Onesource Specialty Pharma’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹1,329 Cr | ₹1,240 Cr |
| Investments | ₹17 Cr | ₹16 Cr |
| Inventories | ₹446 Cr | ₹439 Cr |
| Owed by customers | ₹1,033 Cr | ₹690 Cr |
| Cash and equivalents | ₹14 Cr | ₹36 Cr |
| Total assets | ₹8,586 Cr | ₹8,210 Cr |
| Borrowings | ₹1,484 Cr | ₹1,276 Cr |
| Total liabilities | ₹2,665 Cr | ₹2,379 Cr |
| Shareholders’ equity | ₹5,921 Cr | ₹5,831 Cr |
Source: Onesource Specialty Pharma’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Onesource Specialty Pharma
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Singapore, the United States, Spain, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of pre-clinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed pens, and autoinjectors and self-administration platforms; sterile injectables; soft gelatin capsules; and biologics solutions for recombinant proteins, monoclonal antibodies and biosimilars, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
- Industry
- Biotechnology
- Based in
- Bengaluru
- Employees
- 1,674
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Onesource Specialty Pharma in the last day or two.
Dividends and corporate actions
All companiesNSE lists no dividends or other corporate actions for Onesource Specialty Pharma.
Information only, not investment advice. Prices are delayed.